Lung Cancer | Specialty

Wakelee Shares Latest on Immunotherapy Agents, EGFR Inhibitors in Lung Cancer

August 4th 2017

Heather Wakelee, MD, discusses the latest developments with EGFR inhibitors and immunotherapy agents in non-small cell lung cancer.

FDA Grants Frontline Alectinib Priority Review for ALK-Positive NSCLC

August 3rd 2017

The FDA has granted a priority review to a supplemental new drug application for alectinib (Alecensa) for the frontline treatment of patients with ALK-positive locally advanced or metastatic non–small cell lung cancer.

BRAF/MEK Combo New Standard for BRAF-Mutant NSCLC

August 2nd 2017

Targeted therapies are beginning to carve out a growing number of indications in non–small cell lung cancer, emphasizing the importance of precision medicine.

Future Focus on Combinations, Biomarkers in Metastatic NSCLC

August 1st 2017

The therapeutic paradigm continues to evolve in advanced non-small cell lung cancer, with increased emphasis being placed on rational combinations and biomarkers in the next few years.

FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31st 2017

The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Dr. Bunn on Initial Results of the MYSTIC Trial in Stage IV Lung Cancer

July 28th 2017

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

Frontline Osimertinib Extends PFS in EGFR+ NSCLC

July 28th 2017

Frontline osimertinib (Tagrisso) significantly improved progression-free survival versus standard of care in patients with locally-advanced or metastatic EGFR-positive non–small cell lung cancer.

Therapeutic Options Developing for Non-Driver NSCLC, But Challenges Remain

July 27th 2017

Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.

Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial

July 27th 2017

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma

July 22nd 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has taken a positive position on indications for atezolizumab in non­-small cell lung cancer and urothelial carcinoma.

Nivolumab/Ipilimumab Combo Shows Durable Activity in Small Cell Lung Cancer

July 20th 2017

Mathew D. Hellmann, MD, discusses the first report of the randomized expansion cohort from CheckMate-032 in small cell lung cancer.

NEJM Data Detail Nivolumab Findings in Frontline NSCLC

July 20th 2017

Results now published in the New England Journal of Medicine show that nivolumab (Opdivo) was not superior for progression-free survival compared with chemotherapy as a first-line treatment for patients with NSCLC.

Immunotherapy for Operable NSCLC

July 13th 2017

Novel Immunotherapy Combinations for NSCLC

July 13th 2017

Emerging Immunotherapies and Combinations for NSCLC

July 13th 2017

Unmet Needs: Sequencing After Immunotherapy in NSCLC

July 13th 2017

Questions Surrounding Therapeutic Sequencing for NSCLC

July 13th 2017

Immunotherapy for Relapsed/Refractory NSCLC

July 13th 2017

Early Experience; Immunotherapy + Chemotherapy for NSCLC

July 13th 2017